Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 14/20 | 0.57 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.56 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
| ▸ | JUN | P05412 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.50 |
| ▸ | TMPRSS4 | Q9NRS4 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898802 | 0.93 | DGAT1 (0.53) | P2RX1DGAT1P2RX7P2RX4NFKB1 | |
| SCHEMBL14927270 | 0.92 | DGAT1 (0.52) | P2RX1DGAT1P2RX7P2RX4NFKB1 | |
| SCHEMBL898265 | 0.88 | P2RX1 (0.57) | P2RX1P2RX7P2RX4NFKB1NFKB2 | |
| SCHEMBL899044 | 0.88 | TMPRSS4 (0.57) | P2RX1DGAT1P2RX7P2RX4TMPRSS4 | |
| SCHEMBL898645 | 0.86 | ALDH1A1 (0.63) | P2RX1DGAT1P2RX7P2RX4NFKB1 | |
| SCHEMBL14927268 | 0.86 | DGAT1 (0.56) | DGAT1MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL902905 | 0.86 | KDM4E (0.48) | P2RX1DGAT1P2RX7P2RX4NFKB1 | |
| SCHEMBL14930776 | 0.86 | P2RX1 (0.61) | P2RX1DGAT1P2RX7P2RX4TMPRSS4 | |
| SCHEMBL17470404 | 0.84 | P2RX1 (0.53) | P2RX1P2RX7P2RX4NFKB1NFKB2 | |
| SCHEMBL898584 | 0.82 | TMPRSS4 (0.50) | P2RX1DGAT1P2RX7P2RX4TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576532-B1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9663483-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC | 2016-01-28 | — | — | US | disclosed |
| US-9149527-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9149527-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8722731-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011156321-A9 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011156321-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, EIF4A1 | P2RX1 3876/4885DGAT1 3432/4885P2RX7 3882/4885 |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | P2RX1 3867/4885DGAT1 3272/4885P2RX7 3870/4885 |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | P2RX1 3867/4885DGAT1 3272/4885P2RX7 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.